---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-036519"
form_type: "8-K"
ticker: "TXMD"
cik: "0000025743"
company_name: "TherapeuticsMD, Inc."
filed_at: "2026-03-30T23:59:59+00:00"
generated_at: "2026-05-15T08:28:47.142426+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# TherapeuticsMD reports 2025 full-year net loss of $0.7M, license revenue up 71.6% to $3.0M

## Summary
- Net loss from continuing operations narrowed to $0.7M ($0.06 per share) from $2.3M in 2024.
- License revenue rose 71.6% to $3.0M, primarily driven by the Mayne License Agreement.
- Total operating expenses decreased 5.9% to $7.4M, partly due to lower impairment charges.
- Cash and cash equivalents stood at $7.5M as of December 31, 2025.
- Company continues to evaluate strategic alternatives including M&A or sale of assets.

## SEC filing metadata
- accession: 0001213900-26-036519
- form_type: 8-K
- ticker: TXMD
- cik: 0000025743
- company_name: TherapeuticsMD, Inc.
- filed_at: 2026-03-30T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/25743/000121390026036519/0001213900-26-036519-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/25743/000121390026036519/ea0283239-8k_therapeu.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-036519
- JSON: https://secwatch.observer/filing/0001213900-26-036519.json
- Plain text: https://secwatch.observer/filing/0001213900-26-036519.txt

## Key facts
- Earnings Releases
  TherapeuticsMD, Inc. reported the full year ended December 31, 2025 results: revenue $3.0 million, net income $(0.7) million, EPS $(0.06) per basic and diluted common share.
  - Period: the full year ended December 31, 2025
  - Revenue: $3.0 million
  - Net income: $(0.7) million
  - EPS: $(0.06) per basic and diluted common share
  - Result: reported results
  source text: or $(0.20) per basic and diluted common share, for 2024. License Revenues from Continuing Operations ● License revenue, primarily from the Mayne License Agreement, totaled $3.0 million during the year ended December 31, 2025, an increase of $1.3 million, or 71.6%, compared to $1.8 million in license revenue during the year ended December 31, 2024. The increase
  evidence_url: https://www.sec.gov/Archives/edgar/data/25743/000121390026036519/0001213900-26-036519-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.